SAR100842, an Antagonist of Lysophaphatidic Acid Receptor 1, As a Potential Treatment for Patients with Systemic Sclerosis: Results from a Phase 2a Study

Author: C. Denton, A. Jagerschmidt, M. Jasson, O. Distler and Y. Allanore
Date Published: December-2014
Source: American College of Rheumatology

Preclinical genetic and pharmacological studies suggest a role for Lysophosphatidic acid (LPA) involvement in three key processes of systemic sclerosis: fibrosis, microangiopathy and immunoinflammation. We have assessed SAR100842, a potent selective orally available antagonist of LPA1 receptor and explored safety, skin biomarkers of disease activity and clinical efficacy in patients with diffuse cutaneous SSc (dcSSc) in a phase 2a clinical trial.